Nephro Care India lists at 90% premium
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Dyslipidemia is a critical risk factor for cardiovascular diseases
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
This initiative underscores a steadfast commitment of ONGC to sustainable development and enhanced public health services
Mahatma Gandhi Cancer Hospital & Research Institute has emerged as the leading provider of comprehensive cancer care in Viza
Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Subscribe To Our Newsletter & Stay Updated